Market Research Industry Reports

Melanoma [2016]: Bulletin #3


This edition presents key opinion leader (KOL) views on recent developments in the malignant melanoma (MM) market. Topics covered include: Array BioPharma submission of two New Drug Applications (NDAs) to the US Food and Drug Administration (FDA) for the combination of binimetinib and encorafenib for BRAF-mutant advanced, unresectable or metastatic melanoma; Merck & Co.s updated longer-term overall survival (OS) data from Phase III KEYNOTE-006 study for pembrolizumab (Keytruda), in patients with unresectable or metastatic melanoma and Amgens new data from the Phase II 264 study for talimogene laherparepvec (Imlygic) in combination with ipilimumab (Yervoy).

Business Questions:

How do KOLs view the arrival of Array BioPharmas binimetinib/encorafenib combination to the melanoma treatment landscape?
How does Arrays binimetinib/encorafenib compare to Novartis trametinib/dabrafenib combination?
Could encorafenib/binimetinib, as the new entrant overhaul Novartis lead in this segment?
How do KOLs view the KEYNOTE-006 study data for Keytruda?
What impact will new data for Keytruda have on BristolMyers Squibbs Yervoy?
How do KOLs view the potential of Amgens Imlygic/Yervoy combination therapy?
Is Imlygic /Yervoy combination likely to give way to Imlygic/Keytruda? What do KOLs think?

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.

Melanoma - Pipeline Review, H1 2018

Melanoma - Pipeline Review, H1 2018Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Melanoma - Pipeline Review, H1 2018, provides an overview of the Melanoma (Oncology) pipeline landscape.Melanoma

USD 2500View Report

Global Malignant Melanoma Drug Industry Market Research Report

The Malignant Melanoma Drug market revenue was xx.xx Million USD in 2013, grew to xx.xx Million USD in 2017, and will reach xx.xx Million USD in 2023, with a CAGR

USD 2960View Report

Payer Insights: RA [2016]: Bulletin #3

This edition presents payer views on recent developments in the rheumatoid arthritis (RA) market. Topics include; recent approvals for biosimilar rituximab products in Europe Celltrion/Mundipharmas Truxima (CT-P10) and Sandoz (Novartis)

USD 1045View Report

Multiple Sclerosis [2016]: Bulletin #3

This edition presents the views and insights from three key opinion leaders (KOLs) from the US and Europe on a variety of recent events in the multiple sclerosis (MS) treatment

USD 1045View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)


  • PDF    USD 1045
  • Enterprise Wide Licence    USD 2575
$ 1045

Reports Details

Published Date : Aug 2017
Country :Global
Category :Healthcare
Publisher :FirstWord Dossier
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE


We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube